CellSpring develops blood-based tests for diagnosing early stage cancer. The tests rely on a proprietary exosomal biomarker discovery technology developed at world class research institutes in Switzerland. Detecting cancer early means catching it before a patient even has symptoms -- when the full gamut of therapeutic options is available and most likely to succeed.
Looking for a particular CellSpring employee's phone or email?
The CellSpring annual revenue was $6 million in 2026.
CellSpring is based in Zürich ETH-Hönggerberg, Zurich.
The NAICS codes for CellSpring are [541713, 5417, 541, 54171, 54].
The SIC codes for CellSpring are [873, 87].